Castle Biosciences, Inc. (NASDAQ:CSTL) Shares Acquired by Northern Trust Corp

Northern Trust Corp raised its position in Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 8.7% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 284,587 shares of the company's stock after purchasing an additional 22,657 shares during the period. Northern Trust Corp owned about 1.02% of Castle Biosciences worth $7,584,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. JPMorgan Chase & Co. lifted its position in shares of Castle Biosciences by 165.2% in the third quarter. JPMorgan Chase & Co. now owns 69,409 shares of the company's stock valued at $1,980,000 after acquiring an additional 43,241 shares in the last quarter. Truist Financial Corp lifted its position in shares of Castle Biosciences by 4.6% in the fourth quarter. Truist Financial Corp now owns 21,303 shares of the company's stock valued at $568,000 after acquiring an additional 928 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Castle Biosciences by 15.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 999,466 shares of the company's stock valued at $26,636,000 after acquiring an additional 134,645 shares in the last quarter. MetLife Investment Management LLC lifted its position in shares of Castle Biosciences by 11.4% in the fourth quarter. MetLife Investment Management LLC now owns 16,017 shares of the company's stock valued at $427,000 after acquiring an additional 1,645 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its position in shares of Castle Biosciences by 8.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 22,697 shares of the company's stock valued at $605,000 after acquiring an additional 1,837 shares in the last quarter. 92.60% of the stock is currently owned by hedge funds and other institutional investors.

Castle Biosciences Trading Up 1.3%

NASDAQ CSTL traded up $0.21 during trading hours on Friday, hitting $16.10. 287,423 shares of the company's stock were exchanged, compared to its average volume of 406,893. The business's 50 day moving average is $19.14 and its 200-day moving average is $24.47. Castle Biosciences, Inc. has a 12-month low of $15.66 and a 12-month high of $35.84. The firm has a market capitalization of $464.84 million, a P/E ratio of 80.50 and a beta of 1.19. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.64 and a current ratio of 7.78.

Castle Biosciences (NASDAQ:CSTL - Get Free Report) last released its earnings results on Monday, May 5th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.12). Castle Biosciences had a return on equity of 1.47% and a net margin of 1.95%. The business had revenue of $87.99 million for the quarter, compared to analysts' expectations of $80.40 million. As a group, analysts anticipate that Castle Biosciences, Inc. will post 0.44 EPS for the current fiscal year.

Insiders Place Their Bets

In other Castle Biosciences news, insider Derek J. Maetzold sold 2,130 shares of the company's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $19.52, for a total transaction of $41,577.60. Following the completion of the sale, the insider now directly owns 78,335 shares in the company, valued at $1,529,099.20. This represents a 2.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders sold 27,454 shares of company stock worth $553,030 over the last three months. 6.50% of the stock is owned by insiders.

Wall Street Analyst Weigh In

CSTL has been the topic of several recent research reports. Canaccord Genuity Group reduced their price objective on Castle Biosciences from $42.00 to $37.00 and set a "buy" rating on the stock in a research report on Tuesday, May 6th. Scotiabank reduced their price objective on Castle Biosciences from $44.00 to $40.00 and set a "sector outperform" rating on the stock in a research report on Wednesday. Lake Street Capital reduced their price objective on Castle Biosciences from $40.00 to $35.00 and set a "buy" rating on the stock in a research report on Tuesday, May 6th. Robert W. Baird upped their price objective on Castle Biosciences from $36.00 to $37.00 and gave the company an "outperform" rating in a research report on Friday, February 28th. Finally, Guggenheim set a $30.00 target price on Castle Biosciences and gave the stock a "buy" rating in a research report on Friday, March 28th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Castle Biosciences has a consensus rating of "Buy" and an average target price of $37.00.

About Castle Biosciences

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.